Adrienne Monson – Lifestyle
Author:
Nanoscope Therapeutics
Nanoscope Therapeutics Announces Participation at Eyecelerator® and ARVO 2026 Annual Meetings
April 23, 2026
Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness
April 1, 2026
Nanoscope Therapeutics Receives Orphan Drug Designation in Saudi Arabia for MCO-010, Expands Global Regulatory Leadership in Vision Restoration
March 30, 2026
Nanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease
March 23, 2026